Ionis Gets $25M From GSK For Experimental Hepatitis B Program

Infections caused by the hepatitis B virus, which attacks the liver, are typically treated with drugs that keep the virus from making ever more copies of itself. However, because those treatments reduce but don?t eliminate the virus, patients have to take the drugs indefinitely, according to the World Health Organization. Ionis Pharmaceuticals (NASDAQ: IONS) has [?]